FDA clears Spectrum to remove bioscan for Zevalin treatment Pharmaceutical Business Review Spectrum said with the approval of removing bioscan, patients undergoing treatment with Zevalin will now receive two infusions of rituximab, followed by a 10-minute injection of Zevalin (RRZ). Zevalin (ibritumomab tiuxetan) intravenous injection is ... |
